LiveCount Assay: Concomitant measurement of cytolytic activity and phenotypic characterisation of CD8+ T-cells by flow cytometry

Journal of Immunological Methods

Volumn 311, Issue 1-2, 2006, Pages 31-46

  Devêvre, Estelle ^a   Romero, Pedro ^a   Mahnke, Yolanda D ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

Author keywords

Cancer vaccines; Cytolytic assay; Immune monitoring; Tetramer; Tumour immunity

Indexed keywords

LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; T LYMPHOCYTE ANTIGEN;

ACCURACY; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL SURFACE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY TEST; DEGRANULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOASSAY; IN VITRO STUDY; LIVECOUNT ASSAY; NORMAL HUMAN; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; REPRODUCIBILITY; TUMOR IMMUNOLOGY; UPREGULATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33646085121     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2006.01.011     Document Type: Article

References (44)

1. + T-lymphocyte subsets using quantitative real-time PCR. Scand. J. Immunol. 58 (2003) 601
2. Appay V., Nixon D.F., Donahoe S.M., Gillespie G.M., Dong T., King A., Ogg G.S., Spiegel H.M., Conlon C., Spina C.A., Havlir D.V., Richman D.D., Waters A., Easterbrook P., McMichael A.J., and Rowland-Jones S.L. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192 (2000) 63
3. Assenmacher M., Lohning M., Scheffold A., Manz R.A., Schmitz J., and Radbruch A. Sequential production of IL-2, IFN-gamma and IL-10 by individual staphylococcal enterotoxin B-activated T helper lymphocytes. Eur. J. Immunol. 28 (1998) 1534
4. Balaji K.N., Schaschke N., Machleidt W., Catalfamo M., and Henkart P.A. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J. Exp. Med. 196 (2002) 493
5. Barber D.L., Wherry E.J., and Ahmed R. Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol. 171 (2003) 27
6. Bednarek M.A., Sauma S.Y., Gammon M.C., Porter G., Tamhankar S., Williamson A.R., and Zweerink H.J. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J. Immunol. 147 (1991) 4047
7. + T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281 (2003) 65
8. + T cells store RANTES in a unique secretory compartment and release it rapidly after TcR stimulation. Immunity 20 (2004) 219
9. DiBrino M., Tsuchida T., Turner R.V., Parker K.C., Coligan J.E., and Biddison W.E. HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. J. Immunol. 151 (1993) 5930
10. Gordon K.M., Duckett L., Daul B., and Petrie H.T. A simple method for detecting up to five immunofluorescent parameters together with DNA staining for cell cycle or viability on a benchtop flow cytometer. J. Immunol. Methods 275 (2003) 113
11. Guilloux Y., Lucas S., Brichard V.G., Van Pel A., Viret C., De Plaen E., Brasseur F., Lethe B., Jotereau F., and Boon T. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J. Exp. Med. 183 (1996) 1173
12. Hermans I.F., Silk J.D., Yang J., Palmowski M.J., Gileadi U., McCarthy C., Salio M., Ronchese F., and Cerundolo V. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J. Immunol. Methods 285 (2004) 25
13. Hobeika A.C., Morse M.A., Osada T., Ghanayem M., Niedzwiecki D., Barrier R., Lyerly H.K., and Clay T.M. Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J. Immunother. 28 (2005) 63
14. Keilholz U., Weber J., Finke J.H., Gabrilovich D.I., Kast W.M., Disis M.L., Kirkwood J.M., Scheibenbogen C., Schlom J., Maino V.C., Lyerly H.K., Lee P.P., Storkus W., Marincola F., Worobec A., and Atkins M.B. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother. 25 (2002) 97
15. Kienzle N., Olver S., Buttigieg K., and Kelso A. The fluorolysis assay, a highly sensitive method for measuring the cytolytic activity of T cells at very low numbers. J. Immunol. Methods 267 (2002) 99
16. Knabel M., Franz T.J., Schiemann M., Wulf A., Villmow B., Schmidt B., Bernhard H., Wagner H., and Busch D.H. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat. Med. 8 (2002) 631
17. Lienard D., Rimoldi D., Marchand M., Dietrich P.Y., van Baren N., Geldhof C., Batard P., Guillaume P., Ayyoub M., Pittet M.J., Zippelius A., Fleischhauer K., Lejeune F., Cerottini J.C., Romero P., and Speiser D.E. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun. 4 (2004) 4
18. + T cells specific to a single viral epitope. J. Immunol. 165 (2000) 6214
19. Maecker H.T., and Maino V.C. Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry. Hum. Immunol. 65 (2004) 493
20. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3 (2002) 1061
21. + T cells following immunization. Blood 104 (2004) 1970
22. Perfetto S.P., Chattopadhyay P.K., and Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 4 (2004) 648
23. + T lymphocytes in patients undergoing multiple course peptide vaccination. J. Immunother. 27 (2004) 36
24. Roederer M., De Rosa S., Gerstein R., Anderson M., Bigos M., Stovel R., Nozaki T., Parks D., and Herzenberg L. 8 color, 10-parameter flow cytometry to elucidate complex leukocyte heterogeneity. Cytometry 29 (1997) 328
25. Rubio V., Stuge T.B., Singh N., Betts M.R., Weber J.S., Roederer M., and Lee P.P. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9 (2003) 1377
26. Rubio-Godoy V., Dutoit V., Rimoldi D., Lienard D., Lejeune F., Speiser D., Guillaume P., Cerottini J.C., Romero P., and Valmori D. Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10302
27. Salter R.D., and Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J. 5 (1986) 943
28. Sewell A.K., Gerth U.C., Price D.A., Purbhoo M.A., Boulter J.M., Gao G.F., Bell J.I., Phillips R.E., and Jakobsen B.K. Antagonism of cytotoxic T-lymphocyte activation by soluble CD8. Nat. Med. 5 (1999) 399
29. Sheehy M.E., McDermott A.B., Furlan S.N., Klenerman P., and Nixon D.F. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J. Immunol. Methods 249 (2001) 99
30. + T cells. Nature 401 (1999) 76
31. + T-cell responses. J. Clin. Oncol. 21 (2003) 1562
32. Snyder J.E., Bowers W.J., Livingstone A.M., Lee F.E., Federoff H.J., and Mosmann T.R. Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing. Nat. Med. 9 (2003) 231
33. *0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J. Immunol. 163 (1999) 5512
34. + T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J. Immunother. 27 (2004) 298
35. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115 (2005) 739
36. Steven N.M., Annels N.E., Kumar A., Leese A.M., Kurilla M.G., and Rickinson A.B. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J. Exp. Med. 185 (1997) 1605
37. Storkus W.J., Alexander J., Payne J.A., Cresswell P., and Dawson J.R. The alpha 1/alpha 2 domains of class I HLA molecules confer resistance to natural killing. J. Immunol. 143 (1989) 3853
38. Valmori D., Fonteneau J.F., Lizana C.M., Gervois N., Lienard D., Rimoldi D., Jongeneel V., Jotereau F., Cerottini J.C., and Romero P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160 (1998) 1750
39. *0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide. J. Immunol. 161 (1998) 6956
40. Walker B.D., Flexner C., Birch-Limberger K., Fisher L., Paradis T.J., Aldovini A., Young R., Moss B., and Schooley R.T. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 9514
41. + T cells. J. Exp. Med. 199 (2004) 925
42. Wooldridge L., Hutchinson S.L., Choi E.M., Lissina A., Jones E., Mirza F., Dunbar P.R., Price D.A., Cerundolo V., and Sewell A.K. Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface. J. Immunol. 171 (2003) 6650
43. Xu X.N., Purbhoo M.A., Chen N., Mongkolsapaya J., Cox J.H., Meier U.C., Tafuro S., Dunbar P.R., Sewell A.K., Hourigan C.S., Appay V., Cerundolo V., Burrows S.R., McMichael A.J., and Screaton G.R. A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity 14 (2001) 591
44. Zhang D., Shankar P., Xu Z., Harnisch B., Chen G., Lange C., Lee S.J., Valdez H., Lederman M.M., and Lieberman J. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 101 (2003) 226